SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

PRPO RSS Feed
Add PRPO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/12/2017 7:50:59 AM - Followers: 67 - Board type: Free - Posts Today: 0


Home

Link to coporate website:
http://www.transgenomic.com/

TICKER SYMBOL:TBIO
Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

TRANSFER AGENT:
Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

About:
Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.



Colorectal Cancer Testing



Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"



CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


2013 ASCO CONFERENCE ABSTRACT

http://www.amgen.com/media/media_pr_detail.jsp?year=2013&releaseID=1820728




May. 15, 2013 AMGEN PRESS RELEASE
New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."

 









Contact Information:
Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com

SEC Filings:
http://www.nasdaq.com/asp/quotes_sec.asp?page=filings&symbol=TBIO&selected=TBIO&rpage=sec&


Press Releases:
http://finance.yahoo.com/q?s=TBIO.OB








   
PRPO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TBIO News: Small Company Offering and Sale of Securities Without Registration (d) 07/17/2017 04:16:49 PM
TBIO News: Small Company Offering and Sale of Securities Without Registration (d) 07/14/2017 05:22:41 PM
TBIO News: Small Company Offering and Sale of Securities Without Registration (d) 07/14/2017 05:21:47 PM
TBIO News: Small Company Offering and Sale of Securities Without Registration (d) 07/14/2017 05:21:21 PM
TBIO News: Statement of Ownership (sc 13g) 07/11/2017 04:58:01 PM
PostSubject
#1618   PRPO will ring the opening bell at NASDAQ bradlee 07/12/17 07:50:59 AM
#1617   Precipio 02opida 07/11/17 03:57:06 PM
#1616   PRPO 02opida 07/11/17 03:56:20 PM
#1615   Precipio, Inc. (Nasdaq: PRPO) to Ring The Nasdaq aries4747 07/11/17 02:56:59 PM
#1614   Probably see lots of profit taking today with aries4747 07/06/17 09:27:31 AM
#1613   PRPO shares switched from TBIOD with Etrade. aries4747 07/06/17 09:05:38 AM
#1612   PRPO: Precipio Inc shares surge on Clearbridge Health aries4747 07/05/17 04:40:09 PM
#1611   Think it's going back to $28? MzRed 07/05/17 02:32:42 PM
#1610   I think the tbio, tbiod, and prpo share goodword88 07/05/17 01:49:12 PM
#1609   Did call Etrade, goodword88. Only way to aries4747 07/05/17 12:56:33 PM
#1608   I see. I had some shares of another goodword88 07/05/17 12:49:47 PM
#1607   My Etrade TBIO(D) shares are still sitting there aries4747 07/05/17 12:24:00 PM
#1606   Etrade has it switched to prpo. goodword88 07/05/17 12:10:41 PM
#1605   Thanks for the update, was concerned something was big smooth 07/05/17 11:56:27 AM
#1604   Won't change over, big smooth, until Ameritrade receives aries4747 07/05/17 11:52:46 AM
#1603   On my ameritrade account why has it not big smooth 07/05/17 11:32:09 AM
#1602   Trading Halted! Oh man this is going to News Junky 07/05/17 09:55:38 AM
#1601   Should rock today with the Clearbridge Health news News Junky 07/05/17 09:42:20 AM
#1600   PRPO (12.10): Precipio Announces Agreement with Clearbridge Health aries4747 07/05/17 09:27:38 AM
#1599   PRPO (13.25): Sweet first hit. Up 47%. aries4747 07/03/17 10:18:33 AM
#1598   About Precipio califax 07/03/17 01:31:56 AM
#1597   $PRPO Daily and Weekly Charts http://www.stock $Pistol Pete$ 07/02/17 07:52:45 PM
#1596   Correction: Transgenomic Inc., TBIOD, changed to Precipio Inc., PRPO: Renee 06/30/17 07:54:17 PM
#1595   TBIO moved to the Nasdaq from the OTC: Renee 06/30/17 06:32:37 PM
#1594   11:40: Precipio Inc. (PRPO) Resumed Trading aries4747 06/30/17 12:35:28 PM
#1593   11:35 am: Precipio Inc. (PRPO) Paused due aries4747 06/30/17 12:33:40 PM
#1592   TBIOD now PRPO: Precipio Diagnostics and Transgenomic aries4747 06/30/17 12:08:33 PM
#1591   Nice poppelking 06/21/17 09:08:35 AM
#1590   Transgenomic Prepares for Planned Relisting On NASDAQ califax 06/21/17 08:23:03 AM
#1589   Big, no Huge Yawn. laser777 06/20/17 03:04:49 PM
#1588   Precipio and Transgenomic Announce Experts from Yale and califax 06/20/17 09:04:42 AM
#1587   Didn't see this posted...Yale and Harvard Joining New News Junky 06/16/17 08:20:49 PM
#1586   I would sure like to know how many laser777 06/16/17 11:58:34 AM
#1585   No trades under TBIOD that I can see, north40000 06/13/17 11:49:55 AM
#1584   European Patent Office Confirms Grant of New ICE bradlee 06/13/17 09:51:31 AM
#1583   TBIO effective June 13,2017 a one for 30 Renee 06/12/17 03:14:42 PM
#1582   Transgenomic Stockholders and Precipio Diagnostics Members Approve Merger califax 06/06/17 10:07:58 AM
#1581   Before or after the 30 to 1 reverse bradlee 06/05/17 02:01:32 PM
#1580   The planned effective date of the reverse split califax 06/05/17 10:28:47 AM
#1579   The TBIO shareholder's meeting starts today at 10:00am bradlee 06/05/17 09:59:37 AM
#1578   How does this work with the proxy vote Bearslay3r 05/31/17 04:43:41 PM
#1577   TBIO Pre-merger R/S of 1 for 30 coming aries4747 05/26/17 12:55:11 PM
#1576   Proxy Statement - Merger or Acquistion califax 05/15/17 04:46:41 AM
#1575   Dropping!! big smooth 04/25/17 01:10:58 PM
#1574   Why is this stock dripping like a Rock? big smooth 04/25/17 01:10:38 PM
#1573   Precipio Renews its Exclusive Agreement with Yale School califax 04/22/17 06:28:55 AM
#1572   Today, TBIO announced that it had closed a bradlee 04/17/17 10:29:25 AM
#1571   Looks like the merger is going forward. bradlee 04/13/17 10:07:23 AM
#1570   Amended Statement of Beneficial Ownership (sc 13d/a) califax 04/12/17 09:49:08 AM
#1569   So with this new info, will the stock big smooth 04/07/17 01:30:24 PM
PostSubject